par
Gus Iversen, Editor in Chief | June 11, 2025
PathAI and Northwestern Medicine have entered into a multiyear collaboration to deploy digital pathology infrastructure and codevelop AI tools for diagnostic use.
The partnership includes the adoption of PathAI’s AISight platform across Northwestern Medicine’s network and the launch of joint clinical and research initiatives focused on AI in pathology.
The Boston-based company’s AISight platform will be implemented across Northwestern Medicine’s 11 hospitals, enabling 95 pathologists to review pathology cases digitally, including via remote access. The platform’s cloud-based architecture allows for high-resolution image analysis and centralized case management, supporting workflow efficiency and diagnostic consistency across the system.
Ad Statistics
Times Displayed: 66748
Times Visited: 2188 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
In addition to technology deployment, PathAI and Northwestern Medicine plan to collaborate on research exploring AI applications in areas such as cancer detection, biomarker quantification, and disease pattern recognition. The partnership also includes the codevelopment of new AI diagnostic algorithms using clinical data and feedback from Northwestern Medicine’s pathology department.
“Integrating this technology into our workflow represents a significant leap forward for our pathology program,” said Dr. Daniel J. Brat, chair of pathology at Northwestern Medicine. “By adopting digital pathology and advanced AI tools like AISight, our pathologists will be able to analyze cases more efficiently and with enhanced precision.”
PathAI CEO and cofounder Dr. Andy Beck added, “Collaborating with Northwestern Medicine allows us to bring this mission to life on a large scale. We are thrilled to collaborate with an institution at the forefront of clinical excellence to deploy AISight and jointly develop AI tools that could redefine diagnostic pathology and improve patient outcomes.”
As part of the agreement, Northwestern Medicine will serve as a clinical validation site for new diagnostic models, with an emphasis on integrating AI tools directly into clinical workflows. Both organizations expect the partnership to support broader adoption of AI in clinical pathology and establish a framework for future implementations in healthcare settings.
